23.4 C
New York
Wednesday, June 17, 2026

Tag: progress

newssourceFORcompanyinformationcontent1marketreleases

Heineken Holding N.V. reports transactions under its current share buyback programme

Heineken Holding N.V. reports transactions under its current

Two Weeks Remaining to Enter the Global Sustainability Awards 2026

The Global Sustainability Awards 2026 enters its final submission period, with just two weeks remaining to recognise sustainability excellence

Questerre successfully tests HCCO® Technology in a Commercial-Sized Vessel at PX Energy

THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS

STARTRADER Hosts KTH Alumni Evening in Dubai, Connecting AI, Technology, and Innovation Leaders

The gathering brought together more than 30 professionals across AI, energy, finance, mobility, sustainability, cybersecurity, design, and sports business for a high-level exchange on...

STARTRADER Hosts KTH Alumni Evening in Dubai, Connecting AI, Technology, and Innovation Leaders

The gathering brought together more than 30 professionals across AI, energy, finance, mobility, sustainability, cybersecurity, design, and sports business for a high-level exchange on...

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Author Fari Presents Cambodia’s Path to Peace and Stability in New Book on Hun Sen’s Leadership

ATLANTA, June 14, 2026 (GLOBE NEWSWIRE) -- Author Fari is introducing The Father Who Shielded and Never Left, a book that explores Cambodia's journey toward peace and national development through the leadership experience of Hun Sen, former Prime Minister of Cambodia and current President of the Senate.

Prime Minister Carney expands Canada’s partnership with Ireland across science, technology, and culture

WESTPORT, Ireland, June 14, 2026 /CNW/ - In a more dangerous and divided world, Canada is building our strength at home and diversifying our...

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProgress

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers